Use of tumorigenic cells of human origin for the production of biological and biotechnological medicinal products

  • Email
  • Help
Current version

Public statement

Reference numberCPMP/BWP/1143/00
KeywordsBiotechnological product, biological product, tumorigenic cell, residual cell DNA
DescriptionThis document sets out the current EU regulatory thinking with regard to risk assessment of the purified products derived from tumourigenic cells. It is not legally binding on applicants and may evolve with new scientific developmnets.

Related content

How helpful is this page?

Average rating:

 Based on 20 ratings

Add your rating:

See all ratings
4 ratings
4 ratings
4 ratings
4 ratings
4 ratings

Tell us more